DUBLIN , Dec. 30, 2019 /PRNewswire/ -- The "Asia-Pacific DNA Vaccines Market 2019-2027" report has been added to ResearchAndMarkets.com's offering. The Asia-Pacific DNA vaccines market is expected to make progressive growth at a CAGR of 42.79% in terms of revenue throughout the estimated period of 2019-2027. The important players include Astellas Pharma, Inc., Dendreon Corporation (acquired by Sanpower Group), Eli Lilly and Company, Eurogentec S.A., GlaxoSmithKline, Inc., Inovio Pharmaceuticals, Inc. and Madison Vaccines, Incorporated (MVI). Japan , India , China , South Korea , Australia & New Zealand , ASEAN countries and countries in rest of APAC together constitute the market for DNA vaccines in the Asia-Pacific region. The DNA vaccines market in China is mainly driven by the growing investments by the government of China for clinical trials and development of DNA vaccines towards the treatment of chronic diseases such as cancer, HPV, diabetes, etc. In...